Palleon to Present Preclinical Data on Lead Immuno-Oncology Program, E-602, at SITC Annual Meeting

Palleon to Present Preclinical Data on Lead Immuno-Oncology Program, E-602, at SITC Annual Meeting




Palleon to Present Preclinical Data on Lead Immuno-Oncology Program, E-602, at SITC Annual Meeting

– In vitro and in vivo studies show mechanisms for antitumor activity of E-602 via desialylation of immunosuppressive glycans –

– Company will host a symposium featuring Scientific Co-founder Carolyn Bertozzi and Scientific Advisor James Paulson on glycobiology’s role in immune regulation –

WALTHAM, Mass.–(BUSINESS WIRE)–Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced it will present new preclinical data on the company’s lead immuno-oncology program, E-602, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C., from November 10-14, 2021.

Palleon’s poster highlights recent preclinical data from in vitro and in vivo studies of the company’s most advanced therapeutic candidate, E-602 (formerly known as Bi-Sialidase). E-602 is part of the company’s novel cancer immunotherapy platform, EAGLE (Enzyme-Antibody Glycan-Ligand Editing), which utilizes engineered human sialidase to degrade immunosuppressive sialoglycans.

In addition to the poster presentation, Palleon will be hosting a hybrid (live and virtual) scientific symposium at SITC on November 11th featuring Palleon Scientific Co-Founder Carolyn Bertozzi, Ph.D., Scientific Advisor James Paulson, Ph.D., and Chief Medical Officer David Feltquate, M.D., Ph.D. The session will review the most recent state of the science of sialoglycan-mediated immune regulation and its potential relevance for immuno-oncology therapeutics. To learn more and register to attend, visit this link.

“We’re looking forward to sharing more about the development of our EAGLE platform and the lead program E-602, which we believe is a uniquely powerful way to reverse the immunosuppressive effect of cell-surface sialoglycans,” said Li Peng, Ph.D., Chief Scientific Officer. “These data will inform our upcoming Phase 1 clinical trial of E-602, as well as our growing pipeline of EAGLE therapeutic candidates in oncology.”

Details of the poster presentation are as follows:

Title: Development and engineering of human sialidase for degradation of immunosuppressive sialoglycans to treat cancer

Number: 843

Presenter: Li Peng, Ph.D., Chief Scientific Officer

Details of the symposium are as follows:

Title: Sialoglycan-Mediated Immune Regulation: Glycobiology Meets Immuno-Oncology

Timing: November 11, 2021, 6:30 p.m. – 8:00 p.m. EST

Registration Link

Presenters:

Carolyn Bertozzi, Ph.D.

Anne T. and Robert M. Bass Professor of Chemistry at Stanford University; Baker Family Director of Stanford ChEM-H; Scientific Co-Founder, Palleon Pharmaceuticals

James Paulson, Ph.D.

Cecil H. and Ida M. Green Professor and Co-Chair, Department of Molecular Medicine, and Professor, Department of Immunology and Microbiology, Scripps Research Institute; Scientific Advisor, Palleon Pharmaceuticals

David Feltquate, M.D., Ph.D.

Chief Medical Officer, Palleon Pharmaceuticals

About Palleon Pharmaceuticals

Palleon Pharmaceuticals is the leading biotechnology company developing drugs that harness glyco-immunology to treat cancer and inflammatory diseases. The company’s proprietary platforms overcome scientific hurdles that limited progress in the glycobiology field to create novel therapeutics for devastating diseases characterized by immune system dysfunction. Palleon’s lead program in oncology, E-602, is an enzymatic degrader of immunosuppressive sialoglycans on tumors and immune cells which is expected to enter clinical testing in refractory cancer patients in early 2022. www.palleonpharma.com.

Contacts

Palleon Media Contact
Thomas Stephenson

Ten Bridge Communications

thomas@tenbridgecommunications.com
(617) 448-1803